Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

Information on human papillomavirus (HPV) type distribution is necessary to evaluate the potential impact of current and future HPV vaccines. We estimated the relative contribution (RC) to invasive cervical cancer (ICC) and precancerous cervical lesions of the nine HPV types (HPV 6/11/16/18/31/33/45...

Full description

Saved in:
Bibliographic Details
Published in:Infectious agents and cancer 2012-12, Vol.7 (1), p.38-38, Article 38
Main Authors: Serrano, Beatriz, Alemany, Laia, Tous, Sara, Bruni, Laia, Clifford, Gary M, Weiss, Thomas, Bosch, Francesc Xavier, de Sanjosé, Silvia
Format: Article
Language:English
Subjects:
Adenocarcinoma
Age
Analysis
Cervical cancer
Cervix
Development and progression
Epidemiology
Genotype
Geriatrics
Human papillomavirus
Human papillomavirus vaccines
Invasiveness
Medical research
Medicine, Experimental
Papillomavirus infections
Papillomaviruses
Population growth
Reviews
Risk factors
Squamous cell carcinoma
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b708t-f4bec2b3bfce9da222ffbc326c8cc6c05815a15848e70b853bec7f31b3cb6d413
cites cdi_FETCH-LOGICAL-b708t-f4bec2b3bfce9da222ffbc326c8cc6c05815a15848e70b853bec7f31b3cb6d413
container_end_page 38
container_issue 1
container_start_page 38
container_title Infectious agents and cancer
container_volume 7
creator Serrano, Beatriz
Alemany, Laia
Tous, Sara
Bruni, Laia
Clifford, Gary M
Weiss, Thomas
Bosch, Francesc Xavier
de Sanjosé, Silvia
description Information on human papillomavirus (HPV) type distribution is necessary to evaluate the potential impact of current and future HPV vaccines. We estimated the relative contribution (RC) to invasive cervical cancer (ICC) and precancerous cervical lesions of the nine HPV types (HPV 6/11/16/18/31/33/45/52/58) included in an HPV vaccine currently under development. Estimations on ICC were based on an international study of 8,977 HPV positive cases and estimations on precancerous cervical lesions were extracted from a published meta-analysis including 115,789 HPV positive women. Globocan 2008 and 2010 World Population Prospects were used to estimate current and future projections of new ICC cases. RC of the 9 HPV types in ICC was 89.4%, with 18.5% of cases positive for HPV 31/33/45/52/58. Regional variations were observed. RCs varied by histology, ranging between 89.1% in squamous cell carcinomas (SCC) and 95.5% in adenocarcinomas (ADC). HPV 16/18/45 were detected in 94.2% of ADC. RC of the 9 types altogether decreased with age (trend test p 
doi_str_mv 10.1186/1750-9378-7-38
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_bd74e4cef023490faf50d7a8a0aa0a94</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534334341</galeid><doaj_id>oai_doaj_org_article_bd74e4cef023490faf50d7a8a0aa0a94</doaj_id><sourcerecordid>A534334341</sourcerecordid><originalsourceid>FETCH-LOGICAL-b708t-f4bec2b3bfce9da222ffbc326c8cc6c05815a15848e70b853bec7f31b3cb6d413</originalsourceid><addsrcrecordid>eNqNks-L1DAUx4so7rp69SgFL1665meTXoRl8cfCgh704iW8vCazGdpmTNoB_3szO-uwoytIA23f-_RD-r6pqpeUnFOq27dUSdJ0XOlGNVw_qk4Phcf3nk-qZzmvCRGaaf20OmGcKc6EPK2-f4mzm-YAQx3GDeBcR19DPYXJNVsYSqveAmJ5rcNU3ywjTPUGNmEY4gjbkJZcJzfA7PoaXdoGLKI-ZAfZPa-eeBiye3F3P6u-fXj_9fJTc_3549XlxXVjFdFz44V1yCy3Hl3XA2PMe4uctagRWyRSUwlUaqGdIlZLXnDlObUcbdsLys-qq723j7A2mxRGSD9NhGBuCzGtDKQ54OCM7ZVwAp0njIuOePCS9Ao0ECirE8X1bu_aLHZ0PZb_TzAcSY87U7gxq7g1XEohFCmCi73AhvgPwXEH42h2OZldTkYZrovjzd0mUvyxuDybMWR0wwCTi0s2lFPZlono_0CZZiX1tuMFff0Huo5LmkoyhVKMqY4V7ECtSvgmTD6WXeJOai4kF7ys25GfP0CVq3djwDg5H0r9oQ8wxZyT84eJUGJ2B_nvGby6H8QB_31y-S_P9O6C</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1272279269</pqid></control><display><type>article</type><title>Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Serrano, Beatriz ; Alemany, Laia ; Tous, Sara ; Bruni, Laia ; Clifford, Gary M ; Weiss, Thomas ; Bosch, Francesc Xavier ; de Sanjosé, Silvia</creator><creatorcontrib>Serrano, Beatriz ; Alemany, Laia ; Tous, Sara ; Bruni, Laia ; Clifford, Gary M ; Weiss, Thomas ; Bosch, Francesc Xavier ; de Sanjosé, Silvia</creatorcontrib><description>Information on human papillomavirus (HPV) type distribution is necessary to evaluate the potential impact of current and future HPV vaccines. We estimated the relative contribution (RC) to invasive cervical cancer (ICC) and precancerous cervical lesions of the nine HPV types (HPV 6/11/16/18/31/33/45/52/58) included in an HPV vaccine currently under development. Estimations on ICC were based on an international study of 8,977 HPV positive cases and estimations on precancerous cervical lesions were extracted from a published meta-analysis including 115,789 HPV positive women. Globocan 2008 and 2010 World Population Prospects were used to estimate current and future projections of new ICC cases. RC of the 9 HPV types in ICC was 89.4%, with 18.5% of cases positive for HPV 31/33/45/52/58. Regional variations were observed. RCs varied by histology, ranging between 89.1% in squamous cell carcinomas (SCC) and 95.5% in adenocarcinomas (ADC). HPV 16/18/45 were detected in 94.2% of ADC. RC of the 9 types altogether decreased with age (trend test p &lt; 0.0001), driven by the decrease in older ages of HPV 16/18/45. In contrast, the RC of HPV 31/33/52/58 increased with age. Due to population growth alone, projected estimates of ICC cases attributable to the 9 types are expected to rise from 493,770 new cases in 2012 to 560,887 new cases in 2025.The RCs of individual high risk HPV types varied by cytological and histological grades of HPV-positive precancerous cervical lesions, and there was an under representation of HPV 18 and 45 compared to ICC. The addition of HPV 31/33/45/52/58 to HPV types included in current vaccines could prevent almost 90% of ICC cases worldwide. If the nine-valent vaccine achieves the same degree of efficacy than previous vaccines, world incidence rates could be substantially reduced.</description><identifier>ISSN: 1750-9378</identifier><identifier>EISSN: 1750-9378</identifier><identifier>DOI: 10.1186/1750-9378-7-38</identifier><identifier>PMID: 23273245</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adenocarcinoma ; Age ; Analysis ; Cervical cancer ; Cervix ; Development and progression ; Epidemiology ; Genotype ; Geriatrics ; Human papillomavirus ; Human papillomavirus vaccines ; Invasiveness ; Medical research ; Medicine, Experimental ; Papillomavirus infections ; Papillomaviruses ; Population growth ; Reviews ; Risk factors ; Squamous cell carcinoma ; Vaccines</subject><ispartof>Infectious agents and cancer, 2012-12, Vol.7 (1), p.38-38, Article 38</ispartof><rights>COPYRIGHT 2012 BioMed Central Ltd.</rights><rights>2012 Serrano et al.; licensee BioMed Central Ltd. licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright ©2012 Serrano et al.; licensee BioMed Central Ltd. 2012 Serrano et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b708t-f4bec2b3bfce9da222ffbc326c8cc6c05815a15848e70b853bec7f31b3cb6d413</citedby><cites>FETCH-LOGICAL-b708t-f4bec2b3bfce9da222ffbc326c8cc6c05815a15848e70b853bec7f31b3cb6d413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554470/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1272279269?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23273245$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Serrano, Beatriz</creatorcontrib><creatorcontrib>Alemany, Laia</creatorcontrib><creatorcontrib>Tous, Sara</creatorcontrib><creatorcontrib>Bruni, Laia</creatorcontrib><creatorcontrib>Clifford, Gary M</creatorcontrib><creatorcontrib>Weiss, Thomas</creatorcontrib><creatorcontrib>Bosch, Francesc Xavier</creatorcontrib><creatorcontrib>de Sanjosé, Silvia</creatorcontrib><title>Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease</title><title>Infectious agents and cancer</title><addtitle>Infect Agent Cancer</addtitle><description>Information on human papillomavirus (HPV) type distribution is necessary to evaluate the potential impact of current and future HPV vaccines. We estimated the relative contribution (RC) to invasive cervical cancer (ICC) and precancerous cervical lesions of the nine HPV types (HPV 6/11/16/18/31/33/45/52/58) included in an HPV vaccine currently under development. Estimations on ICC were based on an international study of 8,977 HPV positive cases and estimations on precancerous cervical lesions were extracted from a published meta-analysis including 115,789 HPV positive women. Globocan 2008 and 2010 World Population Prospects were used to estimate current and future projections of new ICC cases. RC of the 9 HPV types in ICC was 89.4%, with 18.5% of cases positive for HPV 31/33/45/52/58. Regional variations were observed. RCs varied by histology, ranging between 89.1% in squamous cell carcinomas (SCC) and 95.5% in adenocarcinomas (ADC). HPV 16/18/45 were detected in 94.2% of ADC. RC of the 9 types altogether decreased with age (trend test p &lt; 0.0001), driven by the decrease in older ages of HPV 16/18/45. In contrast, the RC of HPV 31/33/52/58 increased with age. Due to population growth alone, projected estimates of ICC cases attributable to the 9 types are expected to rise from 493,770 new cases in 2012 to 560,887 new cases in 2025.The RCs of individual high risk HPV types varied by cytological and histological grades of HPV-positive precancerous cervical lesions, and there was an under representation of HPV 18 and 45 compared to ICC. The addition of HPV 31/33/45/52/58 to HPV types included in current vaccines could prevent almost 90% of ICC cases worldwide. If the nine-valent vaccine achieves the same degree of efficacy than previous vaccines, world incidence rates could be substantially reduced.</description><subject>Adenocarcinoma</subject><subject>Age</subject><subject>Analysis</subject><subject>Cervical cancer</subject><subject>Cervix</subject><subject>Development and progression</subject><subject>Epidemiology</subject><subject>Genotype</subject><subject>Geriatrics</subject><subject>Human papillomavirus</subject><subject>Human papillomavirus vaccines</subject><subject>Invasiveness</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Papillomavirus infections</subject><subject>Papillomaviruses</subject><subject>Population growth</subject><subject>Reviews</subject><subject>Risk factors</subject><subject>Squamous cell carcinoma</subject><subject>Vaccines</subject><issn>1750-9378</issn><issn>1750-9378</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNks-L1DAUx4so7rp69SgFL1665meTXoRl8cfCgh704iW8vCazGdpmTNoB_3szO-uwoytIA23f-_RD-r6pqpeUnFOq27dUSdJ0XOlGNVw_qk4Phcf3nk-qZzmvCRGaaf20OmGcKc6EPK2-f4mzm-YAQx3GDeBcR19DPYXJNVsYSqveAmJ5rcNU3ywjTPUGNmEY4gjbkJZcJzfA7PoaXdoGLKI-ZAfZPa-eeBiye3F3P6u-fXj_9fJTc_3549XlxXVjFdFz44V1yCy3Hl3XA2PMe4uctagRWyRSUwlUaqGdIlZLXnDlObUcbdsLys-qq723j7A2mxRGSD9NhGBuCzGtDKQ54OCM7ZVwAp0njIuOePCS9Ao0ECirE8X1bu_aLHZ0PZb_TzAcSY87U7gxq7g1XEohFCmCi73AhvgPwXEH42h2OZldTkYZrovjzd0mUvyxuDybMWR0wwCTi0s2lFPZlono_0CZZiX1tuMFff0Huo5LmkoyhVKMqY4V7ECtSvgmTD6WXeJOai4kF7ys25GfP0CVq3djwDg5H0r9oQ8wxZyT84eJUGJ2B_nvGby6H8QB_31y-S_P9O6C</recordid><startdate>20121229</startdate><enddate>20121229</enddate><creator>Serrano, Beatriz</creator><creator>Alemany, Laia</creator><creator>Tous, Sara</creator><creator>Bruni, Laia</creator><creator>Clifford, Gary M</creator><creator>Weiss, Thomas</creator><creator>Bosch, Francesc Xavier</creator><creator>de Sanjosé, Silvia</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20121229</creationdate><title>Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease</title><author>Serrano, Beatriz ; Alemany, Laia ; Tous, Sara ; Bruni, Laia ; Clifford, Gary M ; Weiss, Thomas ; Bosch, Francesc Xavier ; de Sanjosé, Silvia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b708t-f4bec2b3bfce9da222ffbc326c8cc6c05815a15848e70b853bec7f31b3cb6d413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adenocarcinoma</topic><topic>Age</topic><topic>Analysis</topic><topic>Cervical cancer</topic><topic>Cervix</topic><topic>Development and progression</topic><topic>Epidemiology</topic><topic>Genotype</topic><topic>Geriatrics</topic><topic>Human papillomavirus</topic><topic>Human papillomavirus vaccines</topic><topic>Invasiveness</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Papillomavirus infections</topic><topic>Papillomaviruses</topic><topic>Population growth</topic><topic>Reviews</topic><topic>Risk factors</topic><topic>Squamous cell carcinoma</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Serrano, Beatriz</creatorcontrib><creatorcontrib>Alemany, Laia</creatorcontrib><creatorcontrib>Tous, Sara</creatorcontrib><creatorcontrib>Bruni, Laia</creatorcontrib><creatorcontrib>Clifford, Gary M</creatorcontrib><creatorcontrib>Weiss, Thomas</creatorcontrib><creatorcontrib>Bosch, Francesc Xavier</creatorcontrib><creatorcontrib>de Sanjosé, Silvia</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Infectious agents and cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Serrano, Beatriz</au><au>Alemany, Laia</au><au>Tous, Sara</au><au>Bruni, Laia</au><au>Clifford, Gary M</au><au>Weiss, Thomas</au><au>Bosch, Francesc Xavier</au><au>de Sanjosé, Silvia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease</atitle><jtitle>Infectious agents and cancer</jtitle><addtitle>Infect Agent Cancer</addtitle><date>2012-12-29</date><risdate>2012</risdate><volume>7</volume><issue>1</issue><spage>38</spage><epage>38</epage><pages>38-38</pages><artnum>38</artnum><issn>1750-9378</issn><eissn>1750-9378</eissn><abstract>Information on human papillomavirus (HPV) type distribution is necessary to evaluate the potential impact of current and future HPV vaccines. We estimated the relative contribution (RC) to invasive cervical cancer (ICC) and precancerous cervical lesions of the nine HPV types (HPV 6/11/16/18/31/33/45/52/58) included in an HPV vaccine currently under development. Estimations on ICC were based on an international study of 8,977 HPV positive cases and estimations on precancerous cervical lesions were extracted from a published meta-analysis including 115,789 HPV positive women. Globocan 2008 and 2010 World Population Prospects were used to estimate current and future projections of new ICC cases. RC of the 9 HPV types in ICC was 89.4%, with 18.5% of cases positive for HPV 31/33/45/52/58. Regional variations were observed. RCs varied by histology, ranging between 89.1% in squamous cell carcinomas (SCC) and 95.5% in adenocarcinomas (ADC). HPV 16/18/45 were detected in 94.2% of ADC. RC of the 9 types altogether decreased with age (trend test p &lt; 0.0001), driven by the decrease in older ages of HPV 16/18/45. In contrast, the RC of HPV 31/33/52/58 increased with age. Due to population growth alone, projected estimates of ICC cases attributable to the 9 types are expected to rise from 493,770 new cases in 2012 to 560,887 new cases in 2025.The RCs of individual high risk HPV types varied by cytological and histological grades of HPV-positive precancerous cervical lesions, and there was an under representation of HPV 18 and 45 compared to ICC. The addition of HPV 31/33/45/52/58 to HPV types included in current vaccines could prevent almost 90% of ICC cases worldwide. If the nine-valent vaccine achieves the same degree of efficacy than previous vaccines, world incidence rates could be substantially reduced.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>23273245</pmid><doi>10.1186/1750-9378-7-38</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1750-9378
ispartof Infectious agents and cancer, 2012-12, Vol.7 (1), p.38-38, Article 38
issn 1750-9378
1750-9378
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_bd74e4cef023490faf50d7a8a0aa0a94
source Open Access: PubMed Central; Publicly Available Content Database (Proquest) (PQ_SDU_P3)
subjects Adenocarcinoma
Age
Analysis
Cervical cancer
Cervix
Development and progression
Epidemiology
Genotype
Geriatrics
Human papillomavirus
Human papillomavirus vaccines
Invasiveness
Medical research
Medicine, Experimental
Papillomavirus infections
Papillomaviruses
Population growth
Reviews
Risk factors
Squamous cell carcinoma
Vaccines
title Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T22%3A22%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potential%20impact%20of%20a%20nine-valent%20vaccine%20in%20human%20papillomavirus%20related%20cervical%20disease&rft.jtitle=Infectious%20agents%20and%20cancer&rft.au=Serrano,%20Beatriz&rft.date=2012-12-29&rft.volume=7&rft.issue=1&rft.spage=38&rft.epage=38&rft.pages=38-38&rft.artnum=38&rft.issn=1750-9378&rft.eissn=1750-9378&rft_id=info:doi/10.1186/1750-9378-7-38&rft_dat=%3Cgale_doaj_%3EA534334341%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b708t-f4bec2b3bfce9da222ffbc326c8cc6c05815a15848e70b853bec7f31b3cb6d413%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1272279269&rft_id=info:pmid/23273245&rft_galeid=A534334341&rfr_iscdi=true